Despite the progresses made in recent years in AML treatment with chemotherapy and targeted therapeutics, the survival rate of AML patients remains far from satisfactory, the high recurrence rate of AML patients presents a huge challenge and unmet medical need, successfully targeting LSD1 with small molecules will no doubt provide a novel approach for treating AML patients, mainly by preventing the recurrence of AML patients due to more effective control of LSCs. This evidence concerns the gene KDM1A and acute myeloid leukemia.